Greater China

The banking and insurance regulator publicises performance of controlling the trust sector’s fast growth, FX watchdog’s chief reiterates the need to forestall risk when opening up China’s capital account, and officials name internet security as a key plank in their policy programmes.

HSBC has named Sean Henderson and Sean McNelis as co-heads of debt capital markets, Asia Pacific, with immediate effect, according to a memo seen by GlobalCapital Asia.

Monica Chang, head of loan syndication at ANZ in Taiwan, has left the bank, according to sources.

Chinese optical fibre developer Hengtong Group has hit the international loan market for the first time for a $100m fundraising.

Citi has made two senior changes to its Asia Pacific financial institutions group (FIG), according to an internal memo seen by GlobalCapital Asia on Friday.

Hong Kong was a hotbed of accelerated bookbuild activity this week as two biotechnology firms and a property developer raised a combined HK$6.7bn ($854m) in primary and secondary equity.

Puxin and VCredit Holdings, both of which launched IPOs earlier this week, were covered on their first day of bookbuilding.

China’s market watchdog said companies can submit applications to list China Depositary Receipts from Thursday, declaring the start of trials for the scheme.

Xiaomi Corp had its listing hearing with the Hong Kong Stock Exchange on Thursday, paving the way for investor education to begin on Monday if the IPO is approved.

General Motors’ joint venture sealed a Rmb10.4bn ($1.62bn) deal in the Chinese securitization market on June 6, marking its biggest outing so far. Bankers on the deal said the auto company wanted to bag the cash before onshore rates come under pressure in the second half of the year.

Last week, I had the pleasure of taking a short trip back to the UK for a banker friend’s wedding. The weather was as perfect as a London spring day can be, and I was happy to get away from the usual work grumblings of bankers at the pub.

Hua Medicine has filed for an IPO in Hong Kong under sponsors CLSA and Goldman Sachs, as the promised pipeline of biotechnology issuers begins to materialise following the city’s new listing rules.